Deep Genomics

Company profile

About Deep Genomics

Deep Genomics is a pioneering AI-driven drug discovery company founded in 2015 that leverages Biological Foundation Models (BioFMs) to discover and develop genetic medicines. The company operates at the intersection of artificial intelligence, genomics, and drug development, employing approximately 100 team members with expertise spanning machine learning, molecular biology, clinical development, and software engineering. Deep Genomics' proprietary BioFM Platform enables scalable molecular design and target biology discovery through lab-in-the-loop workflows that integrate AI predictions with experimental validation. The platform includes advanced models like BigRNA, trained on over a trillion signals from high-throughput sequencing datasets, REPRESS for predicting microRNA binding and mRNA degradation, and DeepADAR for designing guide RNAs for ADAR-mediated editing. The company operates experimental facilities totaling over 10,000 square feet across Toronto, Ontario and Cambridge, Massachusetts, where computational and experimental scientists collaborate to design fit-for-purpose datasets and validate therapeutic programs. Deep Genomics serves both internal drug discovery programs and partnerships with major pharmaceutical companies, applying its technology to identify therapeutic targets and design molecules that others would miss.

Company description · Deep Genomics official website

Mission. Building, running and improving the world's best Biological Foundation Models in an effort to transform the field of drug discovery - finding molecules and targets others would miss, and accelerating their development into life changing medicines for patients.